I lead Eureka Nanobioengineering, developing modular, updatable vaccine and immunotherapy platforms that enable customizable formulations, rapid antigen updates, and scalable, cost-effective manufacturing. With a PhD in Chemical Sciences and active academic roles, I translate nanobiotechnology into scalable, regulator‑aware solutions, secure strategic partnerships and dilutive and non‑dilutive funding, and guide programs from proof‑of‑concept to clinical translation and commercial deployment.